DAXOR CORP
No SEC Form 4 filings for $DXR in the last 30 days.
See all $DXR insider activity →Daxor Corporation (DXR) will showcase its FDA-cleared next-gen Blood Volume Analyzer (BVA) at HFSA 2026, featuring 3x faster results and 50% less blood required. Clinical data on heart failure management will be presented, highlighting BVA's accuracy and efficiency. The event runs Oct 9-12, 2026, in Phoenix, AZ.
DAXOR CORP (DXR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000027367 0000027367 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
Daxor Corporation (Nasdaq: DXR) said the USPTO issued U.S. Patent No. 12,635,917 B2 for a “Remote Blood Volume Monitor.” The patent covers systems for continuous, remote tracking of absolute blood volume after a baseline test by combining Daxor blood-volume algorithms with subsequent hematocrit monitoring, including non-invasive wearable optical sensors (e.g., PPG). Daxor said it targets conditions such as heart failure, syncope, anemia, and polycythemia.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning DXR (DAXOR CORP). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent DXR coverage spans financial news, corporate actions and technology.
The product launch may modestly improve Daxor's market visibility and future sales pipeline, but no immediate financial impact is disclosed.
The filing is a routine corporate governance update; it does not disclose new financial guidance, deals, or regulatory outcomes.
Patent issuance strengthens DXR’s IP moat and supports commercialization of remote, continuous blood-volume monitoring for chronic conditions.
Daxor's recent equity issuance raises approximately $8.14 million, which could support growth initiatives. The offering is likely to cause short-term stock dilution but may be viewed positively if it funds expansion.
The FDA clearance of Daxor's new rapid, lightweight blood volume analysis system is a positive development, likely to enhance the company's market position and revenue prospects.
AlphAI scores every news story that mentions DXR with an AI model for sentiment and relevance, and aggregates insider trades from DAXOR CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Daxor Corporation (DXR) will showcase its FDA-cleared next-gen Blood Volume Analyzer (BVA) at HFSA 2026, featuring 3x faster results and 50% less blood required. Clinical data on heart failure management will be presented, highlighting BVA's accuracy and efficiency. The event runs Oct 9-12, 2026, in Phoenix, AZ.
1 min readDAXOR CORP (DXR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000027367 0000027367 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readDaxor Corporation (Nasdaq: DXR) said the USPTO issued U.S. Patent No. 12,635,917 B2 for a “Remote Blood Volume Monitor.” The patent covers systems for continuous, remote tracking of absolute blood volume after a baseline test by combining Daxor blood-volume algorithms with subsequent hematocrit monitoring, including non-invasive wearable optical sensors (e.g., PPG). Daxor said it targets conditions such as heart failure, syncope, anemia, and polycythemia.
4 min readDaxor (DXR) has entered into two significant agreements to support a registered direct equity offering. The company signed a Securities Purchase Agreement with investors to sell 765,958 common shares at $11.75 per share, resulting in approximately $8.14 million in net proceeds. Additionally, Daxor signed a Placement Agency Agreement with Lake Street Capital Markets, which facilitated the transaction that closed on January 26, 2026, with proceeds earmarked for general corporate and growth needs.
2 min readManagement Expects High Demand Driven by Speed, Simplicity, and Clinical Precision ...
2 min readPublished Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients
4 min readDaxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management ...
3 min readWellStar Health System to Highlight New BVA-Driven Strategy That Significantly Reduces Kidney Injury Following LVAD Implantation ...
4 min read
